Observing outcomes of high-precision radiotherapy in metastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study observes the outcomes of high-precision hypo-fractionated radiotherapy in patients with metastatic breast cancer. It focuses on individuals who have undergone or are scheduled to receive advanced radiation therapies such as IMRT, SBRT, or proton therapy. The study aims to gather data on the effectiveness and safety of these treatment approaches in managing distant metastasis in breast cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically confirmed breast cancer
* presence of distant metastasis
* radiation therapy using IMRT, SBRT, or proton therapy is done or planned
* Able and willing to comply with the study protocol

Exclusion Criteria:

* unable to adhere to the study protocol

Where it's running

• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Haeyoung Kim — Samsung Medical Center
• Study coordinator: Haeyoung Kim
• Email: haeyoung0131.kim@samsung.com
• Phone: +82-02-3410-2612

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• UGT1A1 gene and side effects from certain antibody-drug treatments for advanced breast cancer

  This project will test whether common UGT1A1 gene variants explain who gets worse side effects from antibody-drug conjugates (sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan) in adults with advanced breast cancer.

  Recruiting Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Granada, Granada · NCT07582887

• Generative AI Education Tool for Breast Cancer Care

  Researchers are testing an AI-powered teaching tool to help adults with breast cancer understand their care while receiving treatment from UCSF physicians.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07512271

• Pulsed Electric Field Ablation for Metastatic Breast Cancer

  This trial tests a one-time pulsed electric field ablation to treat superficial metastatic breast cancer lesions in adults, guided by imaging.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07487844

• Adaptive biomarker-driven therapies for metastatic breast cancer

  This trial tests whether matching targeted drug combinations to tumor biomarkers helps people with ER+/HER2- or triple-negative metastatic breast cancer who are starting second-line treatment.

  Recruiting at 4 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · New Haven, Connecticut and 5 other locations · NCT07340541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.